Condition
Post-Acute Sequelae of COVID-19
Total Trials
5
Recruiting
1
Active
4
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (3)
P 2 (1)
Trial Status
Active Not Recruiting3
Completed1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05092516Not ApplicableActive Not Recruiting
Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)
NCT06045338Not ApplicableRecruiting
Mind Body Intervention for Long COVID-19
NCT06330376Not ApplicableCompletedPrimary
Diaphragmatic Breathing Exercises for Post-COVID-19 Diaphragmatic Dysfunction (DD)
NCT05225688Active Not Recruiting
Skeletal Muscle in PASC and ME/CFS Patients
NCT05690503Phase 2Active Not RecruitingPrimary
Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial
Showing all 5 trials